TAK Stock Recent News

Takeda Pharmaceuticals (NYSE: TAK) offers a strong cash position and above-average dividend yield, making it an attractive option for income investors seeking international pharma exposure. The company's price/book value of 0.92 suggests it may be undervalued, presenting a potential long-term investment opportunity at a modest price. Risks include foreign currency exchange rate fluctuations and global pressure to reduce drug prices, which could impact profitability and margins.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda's oncology research and development efforts. After an initial collaboration that leveraged Tempus' de-identified multimodal datasets, this new agreement will expand upon.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and that has progressed after chem.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company's ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda's focus on tackling systemic disparities and supporting local leadership in strengthening health infrastructure, empowering h.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the medicine's ongoing shortage in the United States.

Takeda Pharmaceutical Co Ltd TAK stock is trading higher on Wednesday. Earlier today, the European Commission approved Takeda's Adzynma (recombinant ADAMTS13) for treating ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP).

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q1 2025 Results Conference Call July 31, 2024 6:30 AM ET Company Participants Christopher O'Reilly - Head-Investor Relations Christophe Weber - President and Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President of R&D Julie Kim - President of U.S. Business Unit Conference Call Participants Hiroyuki Matsubara - Nomura Securities Steve Barker - Jefferies Shinichiro Muraoka - Morgan Stanley Mike Nedelcovych - Cowen Seiji Wakao - JPMorgan Chase & Co Tony Ren - Macquarie Kasumi Haruta - UBS Investment Bank Hidemaru Yamaguchi - Citigroup Miki Sogi Sanford - Bernstein Christopher O'Reilly Thank you very much for taking time out of your very busy schedule to join us for this first quarter earnings call by Takeda for FY ‘24. I'm the master of ceremony today.

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, announced that it will collaborate with Takeda on immuno-oncology focused research studies. This partnership aims to identify key molecular drivers and predictive markers for treatment efficacy and adverse effects with the primary goal of advancing clinical solutions and improving patient outcomes. Takeda will leverage BostonGene's AI-powered multiomic.